Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aticaprant - Johnson & Johnson Innovative Medicine

Next Previous
Drug Profile

Aticaprant - Johnson & Johnson Innovative Medicine

Alternative Names: AVTX-501; CERC 501; JNJ-3964; JNJ-67953964; JNJ-67953964-AAA; LY-2456302

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Avalo Therapeutics; Eli Lilly and Company; Johnson & Johnson Innovative Medicine
  • Class Antidepressants; Benzamides; Benzene derivatives; Drug withdrawal therapies; Fluorinated hydrocarbons; Pyrrolidines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Major depressive disorder
  • Discontinued Alcoholism; Cocaine-related disorders; Smoking withdrawal

Most Recent Events

  • 06 Mar 2025 Discontinued - Phase-II for Major depressive disorder (Adjunctive treatment) in United Kingdom, Ukraine, Russia, Moldova, Germany and USA due to insufficient efficacy in the target patient population (PO) (9445656)
  • 06 Mar 2025 Discontinued - Phase-III for Major depressive disorder (Adjunctive treatment) in United Kingdom, China, Taiwan, South Africa, Sweden, Slovakia, France, South Korea, Portugal, Spain, Poland, Hungary, Italy, Bulgaria, Czech Republic, Brazil, Belgium, Australia, Argentina and USA due to insufficient efficacy in the target patient population (9445656) (PO)
  • 13 Dec 2024 Johnson & Johnson Innovative Medicine completes a phase III VENTURA-2 trial in Major depressive disorder (Adjunctive treatment) in US, Argentina, Brazil, Bulgaria, China, Czech Republic, France, South Korea, Poland, Slovakia, South Africa, Taiwan (PO) (NCT05550532)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top